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Abstract 
Introduction: The aim of this study was to investigate serum apelin and resistin levels in patients with impaired fasting glucose, impaired 
glucose tolerance, type 2 diabetes and metabolic syndrome. 
Material and methods: The study comprised 18 patients with type 2 diabetes mellitus (T2DM) (nine females, nine males), 18 patients with 
impaired fasting glucose (IFG) (nine females, nine males), 18 patients with impaired glucose tolerance (IGT) (nine females, nine males), 
18 patients with metabolic syndrome (MeS) (nine females, nine males), and 16 healthy individuals (eight females, eight males); serum 
adiponectin, apelin, resistin levels, fasting and postprandial blood glucose, insulin resistance markers, and lipid parameters were measured.
Results: In the study, serum apelin levels were determined to be significantly lower in IGT, MeS, and T2DM groups compared with the 
control group (p = 0.002, p = 0.006, and p < 0.001, respectively). Serum resistin levels were determined to be significantly higher in IGT 
and T2DM groups compared with the control group (p < 0.001 and p < 0.001, respectively). 
Conclusions: Apelin and resistin are thought to affect glucose metabolism and insulin resistance. Apelin is an important indicator in 
individuals with IGT in the prediabetic period and may play a role in preventing diabetic complications and treatment of  T2DM. 
(Endokrynol Pol 2020; 71 (4): 319–324)
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Introduction
Diabetes mellitus (DM) is a chronic metabolic dis-
ease with acute and chronic complications, and high 
morbidity, mortality, and cost to society [1]. Insulin 
resistance means that the normal concentration of 
insulin produces less biological response than normal 
and the effect of stimulating glucose use is reduced [2, 
3]. Genetic factors play an important role among the 
determinants of insulin sensitivity, and various gene 
defects are increasing in number [4, 5]. 
The first studies about resistin show that this expres-
sion is high in obese animal models and that the level of 
circulating resistin is associated with insulin resistance 
in rodents. Resistin is thought to act as a hormone 
working as an insulin antagonist, effective in glucose 
metabolism [6, 7]. It was observed that the risk of 
developing type 2 diabetes (T2DM) also increased in 
individuals with high levels of resistin and with central 
obesity [8, 9]. 
Resistin regulates adipocyte metabolism in mice 
and humans [10]. One of the mechanisms of action 
of thiazolidinedione (TZD), an antidiabetic drug used 
in the treatment of T2DM, which is known to reduce 
insulin resistance, is that it is reported to decrease 
insulin resistance by preventing the production of 
adipocyte-induced resistin [8]. This information shows 
that the increase in circulating resistin is closely related 
to insulin resistance and hyperglycaemia [6, 8, 11]. 
Apelin regulates adipogenesis, fatty acid oxidation, 
and insulin secretion in DM, and apelin-activated 
mechanisms play a role in the pathogenesis of DM 
complications. Apelin improves insulin sensitivity, 
stimulates glucose use in different tissues linked to DM, 
and improves brown adipogenesis. In addition, apelin 
corrects DM-induced kidney hypertrophy, normalises 
obesity-associated cardiac hypertrophy, and negatively 
regulates retinal angiogenesis in diabetic retinopathy 
[12]. Apelin has been described as an increasing new 
adipokine in obese and hyperinsulinaemic humans and 
mice. A positive correlation has been reported between 
plasma apelin levels and BMI. Apelin inhibits insulin 
secretion in mice, and it is thought to have an important 
role in regulating glucose homeostasis. However, the 
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density lipoprotein cholesterol (HDL-C), low-density lipoprotein 
cholesterol (LDL-C), and very low-density lipoprotein (VLDL-C), 
triglycerides (TG) were analysed using an automatic biochemical 
analyser (FUJI DRI-CHEM 4000i, Fuji, Japan). Samples were taken 
from the participants for the measurement of postprandial blood 
glucose. Postprandial blood glucose samples were taken two hours 
after eating. Haemoglobin A1c (HbA1c) concentration was measured 
using the VARIANT II system (Bio-Rad Laboratories, Inc., Hercules, 
CA, USA). 
Measurement of serum resistin levels
Serum resistin levels were studied in accordance with the kit pro-
cedure using the human resistin enzyme-linked immunosorbent 
assay (ELISA) kit (Millipore, catalogue number: EZHADP-51K, 
Missouri, USA). Absorbances were read spectrophotometrically 
on an ELX800 ELISA reader. In plate washings, Bio-tek ELX50 was 
used as an automatic washer. The test results are multiplied by 10 
because of a 1:10 dilution and are indicated in ng/mL. Kit sensitivity: 
< 0.16 ng/mL, measurement range: 0.16–20 ng/mL.
Measurement of serum apelin levels
Serum apelin levels were studied in accordance with the kit proce-
dure using the human apelin enzyme immunoassay kit (Phoenix, 
catalogue no: EK-057-23). Absorbances were read spectrophoto-
metrically on an ELX800 ELISA reader. In plate washings, Bio-tek 
ELX50 was used as an automatic washer. Test results are stated in 
ng/mL. Kit measurement range: 0.07–100 ng/mL.
Statistical analysis
Statistical analysis of the data was performed using the IBM SPSS 
22 statistics package program. The Shapiro-Wilk test was used 
to determine whether the data showed normal distribution. De-
scriptive statistics of the data were expressed as mean ± standard 
deviation for variables with normal distribution in continuous data 
(median [minimum: maximum]) for non-normal distribution vari-
ables, and the frequency for categorical variables as percentage (n 
[%]). Categorical variables were compared using chi-squared tests. 
In comparison of more than two independent groups, one-way 
ANOVA and LSD test for post-hoc analysis were used for normally 
distributed continuous data, and Kruskal-Wallis test and Dunn test 
for post-hoc test for non-normal distributed continuous data. The 
significance level was a = 0.05. 
Results
A total of five groups (four case and one control group) 
and 88 participants were included in the study. Eighteen 
newly diagnosed T2DM patients (nine women, nine 
men), 18 patients with IFG (nine women, nine men), 
18 patients with IGT (nine women, nine men), and 18 
patients with MeS (nine women, nine men). The control 
group consisted of 16 healthy individuals (eight women, 
eight men). When the five groups were compared in 
terms of age (p = 0.632), gender (p = 1.01), and height 
(p = 0.73) there was no statistically significant difference 
between demographic characteristics of groups. There 
was a statistically significant difference between blood 
pressure and biochemical parameters between groups 
(Tab. 1).
Serum apelin levels in T2DM (0.34 ± 0.19 ng/mL) 
(p < 0.001), IGT (0.67 ± 0.34 ng/mL) (p < 0.05), and 
MeS (0.70 ± 0.43 ng/mL) (p < 0.05), control group 
mechanism of inhibitory effects of apelin on insulin 
secretion is not fully known [13]. According to the 
study of Gourdy et al., in humans, injecting high-dose 
(30 nmol/kg-[pyr1]-apelin-35 13) apelin, the apelin in-
creased insulin sensitivity and the apelin/APJ pathway 
in patients with T2DM, confirming that it should be 
considered as a new target for designing alternative 
therapeutic strategies to control [14].
In this study, we aimed to investigate the levels of 
apelin and resistin along with biochemical parameters 
that reflect glucose metabolism in both MeS and T2DM, 
and impaired fasting glucose (IFG) and impaired glu-
cose tolerance (IGT), which are pre-diabetic stages.
Material and methods
Study design and population 
This cross-sectional study was conducted in the internal medicine 
outpatient clinic of a tertiary university hospital between June 
2011 and January 2012. Ethical approval was obtained from the 
Ethics Committee of Non-Interventional Research of Firat Univer-
sity (12.10.2010/11.11). Those who met the inclusion criteria were 
included in the study, and written consent was obtained from all 
participants.
The study inclusion criteria were as follows: (i) having T2DM 
diagnosis according to 1999 World Health Organisation (WHO) 
diagnostic and classification criteria; (ii) being over 30 years old; 
and (iii) having IFG and IGT. On the other hand, the exclusion 
criteria were: (i) having type 1 diabetes mellitus; (ii) having chronic 
hypertension disease; (iii) having congenital anomaly, liver disease, 
chronic renal disease, acute infection, or hypothyroidism; (iv) hav-
ing malignancy; (v) having psychiatric and neurological diseases 
that affect cognitive functions; and (vi) having insulin and oral 
anti-diabetic treatment.  
A total of 88 participants matched by age and gender were in-
cluded in the study. The study was planned with five groups of 
participants. Study groups were designed as group 1 (control group, 
n = 16), group 2 (patients with IFG, n = 18), group 3 (patients 
with impaired glucose tolerance, n = 18), group 4 (patients with 
metabolic syndrome [MeS], n = 18), and group 5 (newly diagnosed 
T2DM patients, n = 18). 
Data collection
Demographic and biochemical parameters of the participants were 
questioned in the study. The age and gender of the participants 
were recorded in the questionnaire form. The anthropometric 
measurements of the participants, i.e. height, weight, and waist 
circumference, were measured by the same researcher. The stand-
ing height of patients was measured with a 0.1 cm sensitive linear 
height scale, and weight in lightweight clothing was measured to 
the nearest 0.1 kg with a sensitive digital scale. The waist circumfer-
ence was measured at minimal inspiration to the nearest 0.1 cm, 
midway between the last rib and the iliac crest. Body mass index 
(BMI) was calculated by dividing body weight by the square of the 
height (kg/m2). The blood pressure of all participants was measured 
with an aneroid sphygmomanometer from both arms after a rest 
period of at least 15 minutes, then the mean blood pressure was 
recorded.
Biochemical investigations
From all patients, whole blood samples (total 5 mL) were obtained 
by venepuncture from a peripheral vein, avoiding haemolysis, 
into plain tubes. Patients were in a resting position in the morning 
hours after an overnight fast. Fasting plasma glucose (FPG), high-
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(1.01 ± 0.30 ng/mL) was significantly higher com-
pared to. Apelin levels in the T2DM (0.34 ± 0.19) 
group, IFG group (0.91 ± 0.22 ng/mL) (p < 0.001), IGT 
group (0.67 ± 0.34 ng/mL) (p < 0.01) and MeS group 
(0.70 ± 0.43 ng/mL) (p < 0.05) compared to significantly 
lower (Tab. 2).










(n = 18) p value
Age (years) 40.94 ± 5.60 40.28 ± 4.33 41.44 ± 4.34 39.17 ± 4.29 40.94 ± 4.60 F = 0.65 p = 0.632




[cm] 72.31 ± 5.25* 89.33 ± 12.09* 95.72 ± 16.5 99.83 ± 10.53 100.72 ± 7.74*
F = 18.03 
p < 0.001
Weight [kg] 68.75 ± 7.66* 77.67 ± 11.47 82.56 ± 15.42 83.72 ± 11.22 81.00 ± 8.21* F = 4.79 p = 0.002
Height [cm] 169 ± 6.62 165 ± 7.04 166 ± 8.29 166 ± 8.3 167 ± 7.59 F = 0.51 p = 0.73
BMI [kg/m2] 24.09 ± 2.41* 28.35 ± 4.4* 30.07 ± 6.45* 30.44 ± 4.01* 29.26 ± 2.86* F = 5.86 p < 0.001









KW = 68.58 
p < 0.001









KW = 72.73 
p < 0.001
LDL-C [mg/dL] 75.0 ± 14.04* 111.44 ± 27.52* 132.83 ± 30.68* 126.06 ± 26.7* 132.89 ± 29.9* F = 13.78 p < 0.001









KW = 29.90 
p < 0.001




































KW = 62.70 
p < 0.001
SBP [mm Hg] 117.19 ± 4.46* 123.33 ± 4.2* 129.72 ± 6.52* 132.5 ± 5.49* 133.06 ± 8.25* F = 21.55 p < 0.001
DBP [mm Hg] 77.81 ± 4.46* 84.17 ± 5.22* 88.61 ± 6.14* 93.89 ± 4.71* 92.5 ± 7.12* F = 22.84 p < 0.001
*Groups with statistical differences between them; T2DM — type 2 diabetes mellitus; F — one-way ANOVA test; KW — Kruskal-Wallis test; IFG — impaired fasting 
glucose; IGT — impaired glucose tolerance; BMI — body mass index; FPG — fasting plasma glucose; PPG — postprandial glucose; LDL-C — low-density lipoprotein 
cholesterol; VLDL-C — very low-density lipoprotein cholesterol; HDL-C — high-density lipoprotein cholesterol; HbA1c — glycated haemoglobin; SBP — systolic blood 
pressure; DBP — diastolic blood pressure










(n = 18) p* value p** value
Apelin  
[ng/mL] 1.01 ± 0.30













*multiple comparison p value; **binary comparison p value; IFG — impaired fasting glucose; IGT — impaired glucose tolerance; MeS — metabolic syndrome; T2DM 
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Serum resistin levels were significantly higher in the 
T2DM (14.5 ± 5.31 ng/mL) and IGT group (9.16 ± 3.06 
ng/mL) compared to the control group (5.11 ± 1.56 
ng/mL) (p < 0.001 and p < 0.01, respectively). Resistin 
levels in the T2DM (14.5 ± 5.31 ng/mL) group; IFG 
(6.40 ± 1.80 ng / mL) was significantly higher compared 
to the IGT (9.16 ± 3.06 ng/mL) and MeS (6.95 ± 2.55 
ng/mL) groups (p < 0.001) (Tab. 3).
Discussion
Diagnosis and intervention in the pre-diabetes stages 
are important for the prevention of diabetes and its 
complications. Therefore, this study was planned 
to determine the levels of a group of adipokines ex-
pressed in the adipose tissues of patients with IFG, IGT, 
MeS, and T2DM, and to contribute to the diagnosis and 
treatment in pre-diabetes and early diabetes stages. 
Steppan et al. [11] reported in their study in mice 
that the level of resistin secreted from adipocytes with 
rosiglitazone, which is an oral antidiabetic, and in-
creased dietary/genetic obesity. This study group found 
that diet-induced obesity in mice resulted in increased 
resistin antibody and insulin activity and improved 
blood sugar. They determined that after recombinant 
resistin administration to normal mice, there was a de-
terioration in glucose tolerance and insulin activity. 
In the same study, it was found that insulin-sensitive 
glucose intake from adipocytes decreased with resistin 
application and increased when resistin was inacti-
vated. Therefore, researchers have argued that resistin 
is a hormone that acts like an insulin antagonist and 
causes diabetes development in obesity.










(n = 18) p* value p** value
Resistin 
[ng/mL] 5.11±1.56













*multiple comparison p value; **binary comparison p value; IFG — impaired fasting glucose; IGT — impaired glucose tolerance; MeS — metabolic syndrome; 









Figure 2. Serum resistin levels of the groups; **p < 0.01, 
compared to the control group; ***p < 0.001, compared to the 








Figure 1. Serum apelin levels belonging to the groups. *p < 0.05, 
compared to the control group; ***p < 0.001, compared to 
the control group; †p < 0.05, compared with T2DM group; 
††p < 0.01, compared with T2DM group; †††p < 0.001, compared 
with the T2DM group
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Serum resistin level, which is one of the main param-
eters of our study, increased significantly in the T2DM 
group. Resistin serum levels were not significant in the 
IFG group compared to the control group (p = 0.243), 
but the increase in the IGT and MeS groups was found 
to be statistically significant (Tab. 3). The increase in se-
rum levels of insulin-resistant expression from adipose 
tissue in IGT, MeS, and T2DM shows that the levels of 
these peptide hormones increase as a result of increased 
hyperglycaemia, which constitutes the starting point of 
our study. It also reveals the theory that these adipo-
kines, which are expressed from adipose tissue, are not 
a cause but a consequence of diabetes. In the process 
that progresses towards T2DM, the increase in plasma 
levels of resistin are probably effective in the develop-
ment of complications of patients with T2DM by using 
the same cellular connection pathways as the resistin 
decreases glucose tolerance and the effect of insulin on 
cells as the same peripheral signal molecule. 
Boucher et al. [15] reported that the synthesis and 
release of apelin from adipose tissue was stimulated 
by insulin. In obese subjects, parallel to the increased 
body fat content and hyperinsulinaemia, an increase 
in plasma apelin levels and m-RNA expressions of the 
apelin in adipocytes was determined. This indicates that 
the synthesis of apelin is induced by obesity and insulin. 
On the other hand, apelin has been shown to increase 
glucose utilisation and inhibit insulin secretion [16, 17]. 
Yue et al. [18] reported that insulin resistance occurred 
in mice with total apelin deficiency and an increase in 
insulin sensitivity by administering apelin to these mice. 
In our study, we found serum apelin levels to be low 
in IGT, MeS (p < 0.05), and T2DM (p < 0.001) compared 
to the control group. Also, compared with the T2DM 
group, we determined that the serum apelin levels of 
BAG (p < 0.001) and MeS and BGT (p < 0.05) groups 
were significantly higher. However, in terms of serum 
apelin levels, there was no statistically significant dif-
ference between the IFG group and the control group 
(p > 0.05) (Tab. 2). This result supports the view that 
apelin increases insulin sensitivity. Similar to our 
study, Zhang et al. [19] found low plasma apelin levels 
in newly diagnosed T2DM patients in their study in 
Chinese people. In this study, it was shown that the 
apelin level was negatively correlated with C-reactive 
protein (CRP), fasting blood glucose (FBG), HbA1c, and 
the Homeostatic Model Assessment for Insulin Resis-
tance (HOMA-IR) and positive correlated with insulin 
sensitivity. In conclusion, they reported that the effect 
of apelin on glucose can indirectly be performed in in-
sulin by adipocyte stimulation in adipocytes. In light of 
all these findings, we can say the following: early stage 
prediabetic individuals who can transform into T2DM 
are also the main metabolic problem insulin resistance. 
Impaired fasting glucose and IGT are considered the 
starting point of all these diabetic disorders. Adipokines 
such as apelin and resistin released from adipose tissue 
appear as molecules responsible for the physiopatho-
logical mechanisms that affect the process of formation 
and development of insulin resistance. Due to the late 
diagnosis of patients with T2DM, mortality due to dia-
betic diseases increases rapidly all over the world. It is 
possible to prevent diabetes and its complications by 
detecting prediabetic cases in the early period.
In this study, we investigated the levels of apelin 
and resistin along with biochemical parameters that 
reflect glucose metabolism in both MeS and T2DM and 
IFG and IGT, which are pre-diabetic stages. Thus, we 
tried to reveal how these parameters change and how 
they affect each other between the insulin resistance 
and the development of diabetes. In our study, while 
serum apelin levels were significantly lower in the 
IGT, T2DM, and MeS groups compared to the control 
group, resistin levels were significantly higher in the 
IGT, MeS, and T2DM groups compared to the control 
group. In the IFG group, no significant difference was 
found in terms of resistin and apelin levels compared 
to the control group. 
As a result, the glucose metabolism, insulin resis-
tance, and the release of these cytokines secreted from 
adipose tissue change positively and negatively. We 
think that changes in the amount of expression of these 
cytokines in individuals with IFG and individuals with 
IGT (during pre-diabetes) can be useful markers in early 
diagnosis and prevention of complications.
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